These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9099167)

  • 41. Prevention of coronary heart disease: incremental cost effectiveness raises issues.
    D'Avanzo WC
    BMJ; 2004 Feb; 328(7436):405; author reply 405. PubMed ID: 14962886
    [No Abstract]   [Full Text] [Related]  

  • 42. Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S).
    Faergeman O; Kjekshus J; Cook T; Pyörälä K; Wilhelmsen L; Thorgeirsson G; Pedersen TR
    Eur Heart J; 1998 Oct; 19(10):1531-7. PubMed ID: 9820992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Direct medical costs of coronary artery disease in the United States.
    Russell MW; Huse DM; Drowns S; Hamel EC; Hartz SC
    Am J Cardiol; 1998 May; 81(9):1110-5. PubMed ID: 9605051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost effectiveness of lowering cholesterol. Study greatly underestimates the cost effectiveness of statin treatment.
    McMurray JJ; Morrison CE
    BMJ; 1996 Nov; 313(7065):1142; author reply 1144. PubMed ID: 8916707
    [No Abstract]   [Full Text] [Related]  

  • 45. A concise review of the cost-effectiveness of coronary heart disease prevention.
    Brown AI; Garber AM
    Med Clin North Am; 2000 Jan; 84(1):279-97, xi. PubMed ID: 10685140
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial). Cambridge Heart Antioxidant Study.
    Davey PJ; Schulz M; Gliksman M; Dobson M; Aristides M; Stephens NG
    Am J Cardiol; 1998 Aug; 82(4):414-7. PubMed ID: 9723625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Simvastatin: building on success.
    Gaw A
    Hosp Med; 2001 Jan; 62(1):29-32. PubMed ID: 11211458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison of neural network models for the prediction of the cost of care for acute coronary syndrome patients.
    Ismael MB; Eisenstein EL; Hammond WE
    Proc AMIA Symp; 1998; ():533-7. PubMed ID: 9929276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness and diagnosis of coronary artery disease.
    Bryg RJ
    Circulation; 1995 Sep; 92(6):1669-70. PubMed ID: 7664458
    [No Abstract]   [Full Text] [Related]  

  • 50. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998.
    Pedersen TR; Olsson AG; Faergeman O; Kjekshus J; Wedel H; Berg K; Wilhelmsen L; Haghfelt T; Thorgeirsson G; Pyörälä K; Miettinen T; Christophersen B; Tobert JA; Musliner TA; Cook TJ;
    Atheroscler Suppl; 2004 Oct; 5(3):99-106. PubMed ID: 15531282
    [No Abstract]   [Full Text] [Related]  

  • 51. A matter of life and death? The Heart Protection Study and protection of clinical trial participants.
    Migrino RQ; Topol EJ;
    Control Clin Trials; 2003 Oct; 24(5):501-5. PubMed ID: 14500049
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The economic impact of preventable ischemic heart disease.
    Smith ES
    Can Med Assoc J; 1977 Sep; 117(5):507-12. PubMed ID: 409476
    [No Abstract]   [Full Text] [Related]  

  • 53. The economic costs of cigarette smoking.
    Hedrick JL
    HSMHA Health Rep; 1971 Feb; 86(2):179-82. PubMed ID: 5101540
    [No Abstract]   [Full Text] [Related]  

  • 54. Secondary prevention in coronary heart disease. Cost effectiveness of treatment must be borne in mind.
    Ferner RE
    BMJ; 1998 Dec; 317(7172):1592. PubMed ID: 9836677
    [No Abstract]   [Full Text] [Related]  

  • 55. [Some economic considerations: the cost and rentability of rehabilitation].
    Simorre R
    Soins Cardiol; 1983 May; (3):41-2. PubMed ID: 6412368
    [No Abstract]   [Full Text] [Related]  

  • 56. From the Centers for Disease Control and Prevention. Public health focus: physical activity and the prevention of coronary heart disease.
    JAMA; 1993 Oct; 270(13):1529-30. PubMed ID: 8371457
    [No Abstract]   [Full Text] [Related]  

  • 57. Resource utilization in the diagnosis and treatment of coronary artery disease.
    Talley JD
    J Interv Cardiol; 1994 Jun; 7(3):271. PubMed ID: 10151057
    [No Abstract]   [Full Text] [Related]  

  • 58. Present status of clofibrate in Canada.
    Lucis OJ
    Can Med Assoc J; 1981 Aug; 125(4):346-8. PubMed ID: 7272885
    [No Abstract]   [Full Text] [Related]  

  • 59. Cost-Effectiveness (CE) of Imaging-Guided Strategies for the Diagnosis of Coronary Artery Disease (CAD): Results From the Evinci Study.
    Lorenzoni V; Pierotti F; Bellelli S; Neglia D; Rovai D; Turchetti G
    Value Health; 2014 Nov; 17(7):A324. PubMed ID: 27200536
    [No Abstract]   [Full Text] [Related]  

  • 60. Simvastatin was cost effective across a broad range of risk and age groups.
    Bryson CL; Fihn SD
    Evid Based Med; 2007 Apr; 12(2):58. PubMed ID: 17400650
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.